Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2025, Astrazeneca (AZN) reported revenue of $14.46 billion, up 11.7% over the same period last year. EPS came in at $1.09, compared to $0.99 in the year-ago quarter.The reported revenue represents a surprise of +3.04% over the Zacks Consensus Estimate of $14.03 billion. With the consensus EPS estimate being $1.09, the company has not delivered EPS surprise.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:BioPharmaceuticals- CVRM- Farxiga- Established RoW: $106 million compared to the $106.86 million average estimate based on three analysts. The reported number represents a change of +2.9% year over year.BioPharmaceuticals- V&I- Europe: $24 million versus the three-analyst average estimate of $15.81 million. The reported number represents a year-over-year change of +242.9%.BioPharmaceuticals- CVRM- Lokelma- Established RoW: $37 million versus the three-analyst average estimate of $34.81 million. The reported number represents a year-over-year change of +32.1%.BioPharmaceuticals- CVRM- Crestor- Established RoW: $32 million compared to the $35.95 million average estimate based on three analysts. The reported number represents a change of -11.1% year over year.Oncology- Tagrisso- Established RoW: $209 million compared to the $215.72 million average estimate based on three analysts. The reported number represents a change of +9.4% year over year.Oncology- Imfinzi- Established RoW: $174 million versus $191.28 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.9% change.Oncology- Lynparza- Established RoW: $69 million compared to the $74.14 million average estimate based on three analysts. The reported number represents a change of +4.6% year over year.Oncology- Calquence- Established RoW: $42 million versus $36.78 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +27.3% change.Oncology- Established RoW: $591 million versus the three-analyst average estimate of $607.27 million. The reported number represents a year-over-year change of +5.4%.BioPharmaceuticals- R&I- Symbicort- Established RoW: $91 million versus $86.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.BioPharmaceuticals- R&I- Fasenra- Established RoW: $44 million compared to the $42.25 million average estimate based on three analysts. The reported number represents a change of +18.9% year over year.BioPharmaceuticals- R&I- Breztri- Established RoW: $25 million versus the three-analyst average estimate of $24.8 million. The reported number represents a year-over-year change of +31.6%.View all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have returned +2.8% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks